Fate Therapeutics, Inc.FATENASDAQ
Loading
R&D Expenses Over TimeContracting
Percentile Rank64
3Y CAGR-30.4%
5Y CAGR-3.0%
Year-over-Year Change
Research and development spending
3Y CAGR
-30.4%/yr
vs +54.6%/yr prior
5Y CAGR
-3.0%/yr
Recent deceleration
Acceleration
-85.1pp
Decelerating
Percentile
P64
Within normal range
vs 5Y Ago
0.9x
Contraction
Streak
3 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| TTM | $107.83M | -20.1% |
| 2024 | $135.00M | -21.8% |
| 2023 | $172.60M | -46.1% |
| 2022 | $320.45M | +48.7% |
| 2021 | $215.52M | +71.6% |
| 2020 | $125.62M | +43.1% |
| 2019 | $87.77M | +56.7% |
| 2018 | $56.02M | +63.1% |
| 2017 | $34.36M | +29.9% |
| 2016 | $26.45M | - |